Revolutionising myeloma treatment through immune profiling
Revolutionising myeloma treatment through immune profiling
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Contribution of constitutional BRCA1 promoter methylation to early-onset and familial breast cancer patients from Pakistan
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
PFS increase but no OS increase for niraparib in advanced ovarian cancer
ESMO 2024: Highlights and analysis